Recorded device evidence

AUDIT MICROCV T-UPTAKE LINEARITY (K112143): indications, design and recorded evidence

The acquired K112143 file contains product-specific indications and users, design and operating principle, performance evidence actually described sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-08. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 0 selected decisions under primary code JJX. 0 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

No quartiles are displayed: this complete-year cohort has fewer than 20 valid pairs.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K112143 ↗ · this pageAUDIT MICROCV T-UPTAKE LINEARITY2011-07-26 → 2012-01-31189Traditional
K170678 ↗Beta-CrossLaps CalCheck 52017-03-06 → 2017-04-0429Traditional
K162173 ↗Elecsys CYFRA 21-1 CalCheck 52016-08-03 → 2017-01-12162Traditional
K162514 ↗Multichem A1c2016-09-08 → 2016-10-2648Abbreviated
K161874 ↗Audit MicroControls Linearity DROP LQ Blood Glucose2016-07-08 → 2016-08-1033Traditional

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K112143 · PDF page 6 ↗ Source 2

Audite       MicroCV"             T-Uptake        Cali brati on/Verification        Set    consists     of   five       levels   of      human        and
bovine        albumin        based          serum        containing         T-Uptake.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K112143 · PDF page 1 ↗ Source 3

The    Audit® MicroCV         Tm     T-Uptake          Cali brationNerification              is a human       and            bovine      albumin
based,          liquid         set     of   QC         material.             Each           level       of the           set contains      T-Uptake            analyte.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Performance evidence actually described

K112143 · PDF page 2 ↗ Source 4

Stability    studies      have          been        performed         to         determine        the        shelf    life      for       the   Audit® MicroCVTM              T-
Uptake          Calibration/Verification            Set.     All      supporting       data      is retained      on         file   at Aalto     Scientific,
Ltd.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK112143 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryAUDIT MICROCV T-UPTAKE LINEARITY [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantAalto Scientific, Ltd. [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeJJX [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2012-01-31 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeTraditional [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2011-07-26 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Performance evidence actually described — what differs in our product?

    The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

    Useful evidence: The cited narrative and full tables, underlying protocols/results and a reviewed comparison with the proposed product.

Work packages and dependencies

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[93989] · record 3ee9f6e36c99e1b7ab693d6751665fc464cb0318d69b77ff8da05bcc93a0575a
  • [5] Complete results array / fda-decision-context:K112143 · record whole dataset partition

FDA 510(k) summary — K112143 ↗

Mon, 27 Feb 2012 05:30:55 GMT · retrieved 2026-10-08

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot 31ba58277a4d4957effc36e840bcb0c9bc2f2ece1617dc3b3e1dbb1a1933cfcd

  • [2] PDF page 6 · record d24a507f1f8a1cd721bfad0da4de9c07ade33a5888fd1f189312fe829589fc5e
  • [3] PDF page 1 · record f1ee0b735b56207bae1d7428243f7b04201f2f154769cece8fb10c2fb13d854a
  • [4] PDF page 2 · record abe151ad8488ea362059b61f5aceca3acec9cc8eb0dae27aa3336dcc2e2acb1b

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services